For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.